Raviteja R. Guddeti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Raviteja R. Guddeti has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Santiago Garcia
Carl and Edyth Lindner Research Center at The Christ Hospital, Cincinnati, Ohio, USA
6 shared publications - Puvi Seshiah
The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital
4 shared publications - Dean J. Kereiakes
The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital
3 shared publications Richard Bae
3 shared publications- Anusha Battineni
Neurology, Cleveland Clinic Foundation, Cleveland, USA
2 shared publications - Bradley Casey
Internal Medicine, Cape Fear Valley Medical Center, Fayetteville, USA
2 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (20)
Evaluating Standard Shielding Versus Novel Enhanced Radiation Protection Devices in the Cardiac Catheterization Laboratory
Background: Enhanced radiation protection devices (ERPDs) have the potential to reduce occupational risks in the cardiac catheterization laboratory. We aimed to investigate scatter radiation exposure to various cardiac catheterization laboratory members using 2 ERPDs. Methods: We prospectively allocated cases to 3 different shielding conditions: standard shielding (group 1), EggNest Protect ERPD (group 2), and EggNest Complete ERPD (group 3). Real‐time dosimetry was used to measure radiation exposure at 3 positions: primary operator (position 1), assistant (position 2), and circulating nurse (position 3). Effective dose equivalent was estimated (annualized to 300 cases/y). Results: A total of 135 patients were included in the study (mean age, 68±11 years; 73% men). For position 1, annualized effective dose equivalent ‐1 doses were 51.4 (19.1–101.3), 7.0 (2.3–21.5), and 2.4 (0.9–6.2) mRem for groups 1, 2, and 3, respectively ( P P P =0.003) standard shielding versus Protect ERPD: 0.3 (−0.4 to 1.2), standard shielding versus Complete ERPD: 0.4 (−0.1 to 1.4). With the use of the EggNest Complete ERPD without a lead apron, annualized total effective doses are ≤1% of the recommended annual maximum for all positions. Conclusions: Compared with standard shielding, ERPDs significantly lowered scatter radiation exposure to all members of the cardiac catheterization laboratory.
- 20 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (20)
Open AccessEvaluating Standard Shielding Versus Novel Enhanced Radiation Protection Devices in the Cardiac Catheterization Laboratory
Background: Enhanced radiation protection devices (ERPDs) have the potential to reduce occupational risks in the cardiac catheterization laboratory. We aimed to investigate scatter radiation exposure to various cardiac catheterization laboratory members using 2 ERPDs. Methods: We prospectively allocated cases to 3 different shielding conditions: standard shielding (group 1), EggNest Protect ERPD (group 2), and EggNest Complete ERPD (group 3). Real‐time dosimetry was used to measure radiation exposure at 3 positions: primary operator (position 1), assistant (position 2), and circulating nurse (position 3). Effective dose equivalent was estimated (annualized to 300 cases/y). Results: A total of 135 patients were included in the study (mean age, 68±11 years; 73% men). For position 1, annualized effective dose equivalent ‐1 doses were 51.4 (19.1–101.3), 7.0 (2.3–21.5), and 2.4 (0.9–6.2) mRem for groups 1, 2, and 3, respectively ( P P P =0.003) standard shielding versus Protect ERPD: 0.3 (−0.4 to 1.2), standard shielding versus Complete ERPD: 0.4 (−0.1 to 1.4). With the use of the EggNest Complete ERPD without a lead apron, annualized total effective doses are ≤1% of the recommended annual maximum for all positions. Conclusions: Compared with standard shielding, ERPDs significantly lowered scatter radiation exposure to all members of the cardiac catheterization laboratory.
- Open Access
- 10 September 2026
- Published by Elsevier in Structural Heart
Trans-Septal BATMAN Simplified– A Step-by-Step Guide
- 10 September 2026
- Published by Elsevier in Structural Heart
Open AccessTrans-Septal BATMAN Simplified– A Step-by-Step Guide
- Open Access
- 19 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (18) , 6608
Redo-Transcatheter Aortic Valve Replacement: Current Evidence and Procedural Considerations
Transcatheter aortic valve replacement (TAVR) has revolutionized the management of severe aortic stenosis (AS), with indications expanding from high and intermediate- to low-surgical risk patients. However, the durability of transcatheter heart valves (THV) is still an ongoing concern, especially in younger, low-risk patients. Redo-TAVR (TAVR-in-TAVR) is feasible and is associated with favorable short-term outcomes in observational studies and registries. Understanding native aortic valve (AV) anatomy and the characteristics of the index THV is critical to the technical and procedural success of redo-TAVR. Cardiac computed tomography angiography (CTA) plays a central role in pre-procedure planning and aids in appropriate valve selection and procedural planning in addition to identifying patients at high risk for coronary occlusion during redo-TAVR. While evidence on redo-TAVR is limited to retrospective observational studies, prospective registries will shed light on the long-term clinical and hemodynamic outcomes.
- 19 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (18) , 6608
Open AccessRedo-Transcatheter Aortic Valve Replacement: Current Evidence and Procedural Considerations
Transcatheter aortic valve replacement (TAVR) has revolutionized the management of severe aortic stenosis (AS), with indications expanding from high and intermediate- to low-surgical risk patients. However, the durability of transcatheter heart valves (THV) is still an ongoing concern, especially in younger, low-risk patients. Redo-TAVR (TAVR-in-TAVR) is feasible and is associated with favorable short-term outcomes in observational studies and registries. Understanding native aortic valve (AV) anatomy and the characteristics of the index THV is critical to the technical and procedural success of redo-TAVR. Cardiac computed tomography angiography (CTA) plays a central role in pre-procedure planning and aids in appropriate valve selection and procedural planning in addition to identifying patients at high risk for coronary occlusion during redo-TAVR. While evidence on redo-TAVR is limited to retrospective observational studies, prospective registries will shed light on the long-term clinical and hemodynamic outcomes.
- Open Access
- 21 August 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (24) , 104751
Percutaneous Removal of Left Atrial Appendage Occlusion Device With a Dedicated Retrieval System
- 21 August 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (24) , 104751
Open AccessPercutaneous Removal of Left Atrial Appendage Occlusion Device With a Dedicated Retrieval System
- Open Access
- 17 June 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 4 (6) , 102620
First-in-human TAVR With Navitor Self-expanding Intra-annular Valve in LVAD–Associated Aortic Regurgitation
- 17 June 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 4 (6) , 102620
Open AccessFirst-in-human TAVR With Navitor Self-expanding Intra-annular Valve in LVAD–Associated Aortic Regurgitation
- Open Access
- 21 January 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 4 (1) , 102439
Understanding Right Heart Flow: Implications for Interatrial Shunt Device Therapy in Heart Failure
- 21 January 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 4 (1) , 102439
Open AccessUnderstanding Right Heart Flow: Implications for Interatrial Shunt Device Therapy in Heart Failure
- Open Access
- 20 March 2023
- Published by Springer Nature in Cureus
- Vol. 15 (3)
Cardiac Metastasis From Renal Cell Carcinoma
While metastasis is common, it is unusual for renal cell carcinoma (RCC) to spread to the heart and even more so without involving the inferior vena cava (IVC). In fact, only a few cases have been reported where RCC has metastasized to the heart without IVC invasion. There have been only a few cases published that show RCC metastasis to the heart without invasion through the IVC. Here, we present an interesting case of a patient that was found to have RCC metastasis to the lungs that had a direct invasion to the left atrium.
- 20 March 2023
- Published by Springer Nature in Cureus
- Vol. 15 (3)
Open AccessCardiac Metastasis From Renal Cell Carcinoma
While metastasis is common, it is unusual for renal cell carcinoma (RCC) to spread to the heart and even more so without involving the inferior vena cava (IVC). In fact, only a few cases have been reported where RCC has metastasized to the heart without IVC invasion. There have been only a few cases published that show RCC metastasis to the heart without invasion through the IVC. Here, we present an interesting case of a patient that was found to have RCC metastasis to the lungs that had a direct invasion to the left atrium.
- Open Access
- 2 January 2023
- Published by Springer Nature in Cureus
- Vol. 15 (1) , e33271
A Case of Symptomatic Paroxysmal Complete Atrioventricular Block
Paroxysmal complete atrioventricular block (PCAB) is clinically characterized by a sudden change from 1:1 atrioventricular (AV) conduction leading to complete heart block. Patients may have a vast array of symptoms, but commonly, PCAB will lead to syncope and possible sudden cardiac death. The literature currently consists of three different types of PCAB: intrinsic paroxysmal atrioventricular block, extensive vagal paroxysmal atrioventricular block, and extrinsic idiopathic paroxysmal atrioventricular block. Currently, there is no single symptom or sign that is specific to a single type of AV block. PCAB is often missed or overlooked because of its unpredictability and no evidence of conduction disease with a normal 1:1 conduction on routine electrocardiograms. Here, we present a case of a 65-year-old female who has been intermittently symptomatic for four years and was found to have PCAB.
- 2 January 2023
- Published by Springer Nature in Cureus
- Vol. 15 (1) , e33271
Open AccessA Case of Symptomatic Paroxysmal Complete Atrioventricular Block
Paroxysmal complete atrioventricular block (PCAB) is clinically characterized by a sudden change from 1:1 atrioventricular (AV) conduction leading to complete heart block. Patients may have a vast array of symptoms, but commonly, PCAB will lead to syncope and possible sudden cardiac death. The literature currently consists of three different types of PCAB: intrinsic paroxysmal atrioventricular block, extensive vagal paroxysmal atrioventricular block, and extrinsic idiopathic paroxysmal atrioventricular block. Currently, there is no single symptom or sign that is specific to a single type of AV block. PCAB is often missed or overlooked because of its unpredictability and no evidence of conduction disease with a normal 1:1 conduction on routine electrocardiograms. Here, we present a case of a 65-year-old female who has been intermittently symptomatic for four years and was found to have PCAB.
- 3 August 2021
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 98 (6) , E954-E962
Impact of gender on in‐hospital mortality and 90‐day readmissions in patients undergoing transcatheter edge‐to‐edge mitral valve repair: Analysis from the National Readmission Database
Background: Patients undergoing transcatheter edge‐to‐edge mitral valve repair (TEER) carry a high risk of rehospitalization due to disease, procedure, patient, hospital, and system related factors.Aims: We aimed to explore the impact of gender on in‐hospital mortality and 90‐day readmissions in patients undergoing TEER.Methods: We utilized the National Readmission Database from 2012 to 2018 to identify individuals who underwent TEER for mitral regurgitation. Gender‐based differences in in‐hospital mortality and 90‐day readmissions were explored using multivariable logistic regression models.Results: Between 2012 and 2018, an estimated 21,415 TEER procedural hospitalizations were identified, of which 9893 (46.2%) were in women and 11,522 (53.8%) were in men. Compared with men, women were older, from a lower socioeconomic status but had a lower co‐morbidity burden. In‐hospital mortality rate during the index hospitalization was similar in women and men (2.1% vs. 2.1%, p = 0.908). Ninety‐day all‐cause and heart failure readmission rates were significantly higher in women compared to men (30.2% vs. 25.4%; p < 0.001 and 28.1% vs. 23.9%; p = 0.020 respectively). In a multivariable analysis, women had 36% greater odds of 90‐day readmission compared to men (adjusted odds ratio [aOR] 1.36, 95% CI: 1.22–1.52; p < 0.001). Trend analysis revealed no significant improvement in rates of 90‐day readmission during the observation period for men or women (p = 0.245, p = 0.429, respectively).Conclusions: Following TEER, there has been no significant improvement in 90‐day readmission rates between 2012 and 2018. Female gender is associated with higher 90‐day all‐cause and heart failure readmission rates.
- 3 August 2021
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 98 (6) , E954-E962
Impact of gender on in‐hospital mortality and 90‐day readmissions in patients undergoing transcatheter edge‐to‐edge mitral valve repair: Analysis from the National Readmission Database
Background: Patients undergoing transcatheter edge‐to‐edge mitral valve repair (TEER) carry a high risk of rehospitalization due to disease, procedure, patient, hospital, and system related factors.Aims: We aimed to explore the impact of gender on in‐hospital mortality and 90‐day readmissions in patients undergoing TEER.Methods: We utilized the National Readmission Database from 2012 to 2018 to identify individuals who underwent TEER for mitral regurgitation. Gender‐based differences in in‐hospital mortality and 90‐day readmissions were explored using multivariable logistic regression models.Results: Between 2012 and 2018, an estimated 21,415 TEER procedural hospitalizations were identified, of which 9893 (46.2%) were in women and 11,522 (53.8%) were in men. Compared with men, women were older, from a lower socioeconomic status but had a lower co‐morbidity burden. In‐hospital mortality rate during the index hospitalization was similar in women and men (2.1% vs. 2.1%, p = 0.908). Ninety‐day all‐cause and heart failure readmission rates were significantly higher in women compared to men (30.2% vs. 25.4%; p < 0.001 and 28.1% vs. 23.9%; p = 0.020 respectively). In a multivariable analysis, women had 36% greater odds of 90‐day readmission compared to men (adjusted odds ratio [aOR] 1.36, 95% CI: 1.22–1.52; p < 0.001). Trend analysis revealed no significant improvement in rates of 90‐day readmission during the observation period for men or women (p = 0.245, p = 0.429, respectively).Conclusions: Following TEER, there has been no significant improvement in 90‐day readmission rates between 2012 and 2018. Female gender is associated with higher 90‐day all‐cause and heart failure readmission rates.
- 11 May 2021
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 97 (6) , 1174-1175
With great power comes great responsibility: When and how to use the retrograde approach to chronic total occlusion interventions
Key Points: The retrograde approach to chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is a powerful tool for successful CTO crossing, especially in complex occlusions. Compared with antegrade‐only CTO PCI, the retrograde approach is associated with increased risk of periprocedural complications. The retrograde approach should be used when the anticipated benefits outweigh the potential risks and should be performed in a meticulous, systematic, and stepwise fashion to maximize the likelihood of success and minimize the risk of complications.
- 11 May 2021
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 97 (6) , 1174-1175
With great power comes great responsibility: When and how to use the retrograde approach to chronic total occlusion interventions
Key Points: The retrograde approach to chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is a powerful tool for successful CTO crossing, especially in complex occlusions. Compared with antegrade‐only CTO PCI, the retrograde approach is associated with increased risk of periprocedural complications. The retrograde approach should be used when the anticipated benefits outweigh the potential risks and should be performed in a meticulous, systematic, and stepwise fashion to maximize the likelihood of success and minimize the risk of complications.